CEDO
27.7.2021 09:02:17 CEST | Business Wire | Press release
Cedo , one of Europe’s largest manufacturers of household waste bags made with recycled plastics, has made its first major leap towards becoming a climate neutral business, powering its UK factory in Telford and offices in Paris and Mönchengladbach with 100 per cent renewable energy. Its UK business, based in Shropshire, has also achieved its target of sending zero manufacturing waste to landfill.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005178/en/
More than 23 per cent of Cedo’s global operations now use 100 per cent renewable energy, with suppliers including green energy provider Total and PGE S.A in Poland. Cedo’s remaining factories in Vietnam, Poland and the Netherlands are also on target to achieve climate neutrality over the next few years.
“Cedo’s aim is to become a climate neutral business worldwide by 2030. By increasing our use of renewable energy year-on-year while focusing our efforts on achieving zero manufacturing waste to landfill, we are making rapid progress towards our goal,” said Rik De Vos, CEO of Cedo. “Our next ambition is to continue to pursue a more circular approach in our stewardship of raw materials, while creating a sustainable business that is no longer reliant on fossil fuel-based virgin polymers.
“In the very near future every Cedo non-food product will be fully recycled and recyclable. We believe that keeping our homes clean, safe and tidy in an environmentally friendly way should be as simple as putting out the bins,” said De Vos.
Established in 1965, Cedo is one of the world’s leading plastics recycling businesses, specialising in the recycling of post-consumer household packaging waste such as plastic packaging and clingfilm. Every year, the business uses more than 80,000 tons of recycled plastic to make over 4 billion refuse sacks and bin liners from factories based in Poland, the Netherlands, Vietnam and the UK, operating one of the largest flexible plastic film recycling centres in Europe.
Cedo products from bin liners to food wrap and latex gloves can be found in supermarkets and retailers in 34 countries. In the UK, 93% of the plastic used by Cedo to manufacture non-food products is from recycled sources.
As we approach Earth Overshoot Day on 29 July, Cedo is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.
- Ends –
About Cedo
Established in 1965, Cedo is one of Europe's largest and most sustainable suppliers of refuse sacks made from recycled plastics, as well as other consumer household products designed to protect and store food. For more than thirty years it has led the development of recycling mixed plastic film recovered from households to give more plastic a second life, creating 100% recycled and 100% recyclable products designed to keep European households, workplaces and leisure spaces clean, healthy and safe.
As founding signatories to both the Ellen MacArthur Foundation’s New Plastics Economy Global Commitments and the European Plastics Pact, Cedo is working with partners including NGO The Plastic Bank to create new solutions and interventions to address the challenges of building a new plastics economy.
For two years, Cedo has been recognised by the Sunday Times top track 250 (fast growing medium sized privately owned business). By 2030 the business will be climate neutral across its global operations.
For more information please visit cedo.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005178/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
